MarDee Haring-Layton - 30 Jan 2026 Form 4 Insider Report for Dare Bioscience, Inc. (DARE)

Reporting relationship: Chief Accounting Officer
Issuer ticker: DARE
Reported as of: 30 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Feb 2026, 16:05:49 UTC
Prior SEC filing: 04 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ MarDee Haring-Layton

Key filing fact

MarDee Haring-Layton filed Form 4 for Dare Bioscience, Inc. (DARE) on 02 Feb 2026.

Key facts

This page summarizes MarDee Haring-Layton's Form 4 filing for Dare Bioscience, Inc. (DARE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Feb 2026, 16:05.

Change

Previous filing in this sequence was filed on 04 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001535596 Primary reporting owner

Haring-Layton MarDee

Relationship: Chief Accounting Officer
Address: C/O DARE BIOSCIENCE, INC., 3655 NOBEL DRIVE, SUITE 260, SAN DIEGO
Signature: /s/ MarDee Haring-Layton
Signature date: 02 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DARE transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +49,000
Change %
Price: $0.000000
Shares after: 49,000
Date: 30 Jan 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 49,000
Exercise price: $1.81
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer.